Recent investigations into retatrutide, a dual stimulant for GLP-1 and GIP receptors, are revealing encouraging results in managing excess mass and type 2 disease. Preclinical information suggest a unique action https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/